The firm plans to enroll US patients into the trial of GEB-101 in the second quarter, having launched an investigator-initiated trial in China.

The US Food and Drug Administration (FDA) has cleared GenEditBio Limited’s Investigational New Drug (IND) application to ...

EBT-101 is a potentially curative, one-time CRISPR-based treatment which makes two cuts in integrated retroviral DNA to remove large portions of the HIV genome and prevent HIV from escaping and ...

CRISPR has increasingly gained popularity in its role with immunotherapy over the years. This short video introduces CRISPR as related to immunotherapy, as well as its capabilities now and into the ...

CRISPR became big in 2025, bringing advances for serious Indian health risks, which will continue in the coming year ...

凯茜·伍德的ARK ETF公布了2025年12月26日星期五的每日交易情况，显示其大量购入了 CRISPR Therapeutics AG (NASDAQ:CRSP) 股票。ARK总共购入了23,170股，其中19,965股添加到其 ARKK ETF ，3,205股添加到其 ARKG ETF ...

The USPTO has ruled there is “no interference in fact” in the closely-watched dispute over CRISPR patents between the University of California and the Broad Institute, reports MIT Technology Review.